buyRating News & Analysis
6 articles
Market Mood
ADP Maintains Buy Rating with $270 Price Target Amid Growth Potential
On April 20, Guggenheim maintained a Buy rating for Automatic Data Processing, Inc. (ADP) with a price target of $270. They argue that the market is underestimating ADP's growth potential, particularly with its enterprise human capital management tool, Lyric. Guggenheim's analysis highlights Lyric's effectiveness in complex payroll environments and its ability to work alongside existing systems like Workday and SAP. ADP is expected to release its fiscal Q3 2026 earnings on April 29, with projected revenue of approximately $5.85 billion and a GAAP EPS estimate of $3.30.
Read More
Accenture (ACN) Analysts Favorable with 70% Buy Ratings
Accenture plc (ACN) has received Buy ratings from 70% of the 30 analysts covering it, reflecting positive market sentiment. The average 12-month price target indicates a potential upside of more than 26% from the current price. On April 20, 2026, at Hannover Messe in Germany, Accenture announced its partnership with Avanade and Microsoft to develop an agentic factory intelligence system. This system aims to enhance manufacturing through collaboration among AI agents, human workers, and machinery, with initial implementations from Kruger and Nissha Metallizing Solutions expected later this year.
Read More
Target (TGT) PT Raised to $140 from $130 by Guggenheim Partners
Guggenheim Partners increased the price target for Target Corporation (TGT) from $130 to $140 on April 20, reiterating a Buy rating. This adjustment reflects expected strong performance in Q1, with higher EBIT and EPS estimates that are now at "Street-high levels." Target also announced a collaboration with Parke on April 21, featuring a new collection set to launch on April 25, which includes nearly 60 items focusing on women's apparel and accessories. The combination of strong earnings outlook and innovative partnerships may enhance investor confidence in TGT's market position.
Read More
Rosenblatt Reiterates Buy Rating on Palantir Amid Missile Defense Contract Potential
Rosenblatt has maintained a Buy rating on Palantir Technologies due to its potential to secure missile defense contracts. The firm's analysts highlight the strategic importance of defense contracts for growth within the industry. This announcement comes at a time when defense spending is anticipated to increase, potentially impacting Palantir's market performance positively. Specific sales projections or financial figures were not disclosed in the report.
Read More
Immunic Stock Surges Following Guggenheim Buy Recommendation
Immunic's stock experienced a notable increase after Guggenheim initiated coverage with a 'Buy' rating. This development signals confidence in the company's potential, likely impacting investor sentiment and trading volumes. Specific percentage changes or trading volume data were not provided in the article, but the initiation of coverage by a significant firm indicates a positive outlook for the stock's future performance. This move may lead to increased market interest in Immunic shares.
Read More
Stifel Maintains Buy Rating on Amdocs with $88 Price Target
Stifel has reiterated its 'Buy' rating on Amdocs stock and set a price target of $88. This recommendation is rooted in Stifel's analysis of Amdocs' market position and growth potential. Maintaining a positive outlook on the stock could influence investor sentiment and trading. As of the last review, Amdocs represents a strategic investment opportunity in the tech sector at this price target.
Read More